The content on this site is intended for healthcare professionals only
Corrine Williams speaks to ecancer at the APAO 2019 meeting in Boston about the latest research in lymphoma.
She outlines the benefits of oral oncolytics, but also the fact that they are currently an indefinite treatment. The CLL-14 trial is looking to change this.
Corrine finishes by discussing the latest long term data on ibrutinib.
Revolutionising myeloma treatment through immune profiling
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
